The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet

Journal of Hypertension

Volumn 23, Issue 10, 2005, Pages 1879-1886

  Takai, Shinji ^a   Jin, Denan ^a   Sakaguchi, Masato ^a   Muramatsu, Michiko ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Atherosclerosis; Monkey

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HEART RATE; INTRAVASCULAR ULTRASOUND; LIPID STORAGE; MALE; MONKEY; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL;

EID: 29244459706     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000182527.52063.32     Document Type: Article

References (23)

1. Dzau VJ. Pathobiology of atherosclerosis and plaque complications. Am Heart J 1994; 128:1300-1304.
2. Chobanian AV. Can antihypertensive drugs reduce atherosclerosis and its clinical complications? Am J Hypertens 1994; 7:119S-125S.
3. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
4. Song K, Shiota N, Takai S, Takashima H, Iwasaki H, Kim S, et al. Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high- cholesterol fed Cynomolgus monkeys. Atherosclerosis 1998; 138:171-182.
5. Miyazaki M, Takai S. Antiatherosclerotic effect of alacepril, an angiotensin-converting enzyme inhibitor, in monkeys fed a high-cholesterol diet. Hypertens Res 1999; 22:49-54.
6. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol 1999; 128:523-529.
7. Takai S, Kim S, Sakonjo H, Miyazaki M. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. J Hypertens 2003; 21:361-369.
8. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101:1586-1593.
9. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Ortega L, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95:1532-1541.
10. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99:2027-2033.
11. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996; 226:862-868.
12. Nakano N, Morishita R, Moriguchi A, Nakamura Y, Hayashi SI, Aoki M, et al. Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-beta in blood vessels: potential role of HGF in cardiovascular disease. Hypertension 1998; 32:444-451.
13. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103:919-925.
14. Masuda J, Terashima M, Yokoyama M. Improved reproducibility of intravascular ultrasound assessment of coronary in-stent neointima with the use of an echogenic contrast agent. Jpn Circ J 2001; 65:632-636.
15. Kitamoto S, Nakano K, Hirouchi Y, Kohjimoto Y, Kitajima S, Usui M, et al. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates. Arterioscler Thromb Vasc Biol 2004; 24:1522-1528.
16. Takai S, Jin D, Sakaguchi M, Muramatsu M, Ishii K, Kirimura K, et al. Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model. Hypertens Res 2004; 27:517-522.
17. Dol F, Martin G, Staels B, Mares AM, Cazaubon C, Nisato D, et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2001; 38:395-405.
18. Ni W, Kitamoto S, Ishibashi M, Usui M, Inoue S, Hiasa K, et al. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-Induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004; 24:1-7.
19. Proudfoot JM, Croft KD, Puddey IB, Beilin LJ. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 2003; 305:846-853.
20. Kohno M, Ohmori K, Nozaki S, Mizushige K, Yasunari K, Kano H, et al. Effects of valsartan on angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertens Res 2000; 23:677-681.
21. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653-1659.
22. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101:2349-2354.
23. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99:2027-2033.